4D Molecular Therapeutics (FDMT) Change in Receivables (2020 - 2022)
4D Molecular Therapeutics (FDMT) reported Change in Receivables of -$47000.0 for Q1 2022, up 90.98% year-over-year from -$24610.1 in Q1 2021, and up 93.68% quarter-over-quarter from -$744000.0 in Q4 2021.
4D Molecular Therapeutics (FDMT) Change in Receivables (2020 - 2022) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 3 years of Change in Receivables data on file, last reported at -$47000.0 in Q1 2022.
- Change in Receivables for Q1 2022 came in at -$47000.0, up 90.98% year-over-year; the trailing twelve-month figure through Dec 2022 was -$47000.0 (up 96.73% YoY), and the FY2022 annual result was -$47000.0, up 96.73% from the prior year.
- Change in Receivables improved to -$47000.0 in Q1 2022 per FDMT's latest filing, from -$744000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $590000.0 in Q4 2020 and troughed at -$744000.0 in Q4 2021.
- A 3-year average of -$108666.7 and a median of -$99000.0 in 2020 frame the typical range for Change in Receivables.
- On a YoY basis, Change in Receivables climbed as much as 267.55% in 2021 and fell as far as 426.26% in 2021.
- A 3-year view of Change in Receivables shows it stood at $590000.0 in 2020, then tumbled by 226.1% to -$744000.0 in 2021, then jumped by 93.68% to -$47000.0 in 2022.
- Business Quant data shows FDMT's Change in Receivables at -$47000.0 in Q1 2022, -$744000.0 in Q4 2021, and -$427000.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -47,000.00 |
| Mar 31, 2022 | -47,000.00 |
| Dec 31, 2021 | -744,000.00 |
| Dec 31, 2021 | -744,000.00 |
| Sep 30, 2021 | -427,000.00 |
| Sep 30, 2021 | -427,000.00 |
| Jun 30, 2021 | 253,000.00 |
| Jun 30, 2021 | 253,000.00 |
| Mar 31, 2021 | -521,000.00 |
| Mar 31, 2021 | -521,000.00 |
| Dec 31, 2020 | 590,000.00 |
| Dec 31, 2020 | 590,000.00 |
| Sep 30, 2020 | 168,000.00 |
| Sep 30, 2020 | 168,000.00 |
| Jun 30, 2020 | -151,000.00 |
| Jun 30, 2020 | -151,000.00 |
| Mar 31, 2020 | -99,000.00 |
| Mar 31, 2020 | -99,000.00 |